Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13644
Country/Region: South Africa
Year: 2014
Main Partner: University of Cape Town
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $0 Additional Pipeline Funding: $507,080

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The University of Cape Town prioritizes pharmacovigilance approaches that are most efficient at assessing the burden of drug-related morbidity and mortality on the healthcare system. The focus is on Adverse Drug Reaction (ADR) in HIV infected patients, but the proposed multi-center hospital surveys will also evaluate serious ADRs in HIV negative patients. The aim, wherever possible, is to strengthen pharmacovigilance for all medicines.

The approaches are intended to identify gaps and future priorities of the national drug policy, strengthen and evolve the existing national pharmacovigilance structure, and strengthen the link between drug safety surveillance and improving the quality of care for patients infected with HIV/AIDS. The goals are to develop systems to assess the burden of clinically significant adverse drug reactions and to create a sustainable and responsive system for reporting of ADRs, which links ADR reporting to provision of information and clinical advice.

The objectives are:

a) To perform a gap analysis and landscaping exercise of existing pharmacovigilance structures and activities, in collaboration with the NDOH; to describe the frequency, nature and preventability of ADRs which result in hospital admission, and ADRs occurring during admission;

b) To determine to what extent ARV and anti-tubercular medicines contribute to the burden of adverse drug reactions resulting in hospitalisation and occurring in hospital; and

c)To strengthen the capacity to collect ART program surveillance data by establishing reasons for treatment-limiting toxicities in treating adults and children, broadly representative of the national program, with the possibility of expansion to further sites.

Mechanism Allocation by Budget Code for Selected Year
Strategic Information (HVSI) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

This mechanism has no published performance targets or indicators.